[go: up one dir, main page]

RU2018104283A3 - - Google Patents

Download PDF

Info

Publication number
RU2018104283A3
RU2018104283A3 RU2018104283A RU2018104283A RU2018104283A3 RU 2018104283 A3 RU2018104283 A3 RU 2018104283A3 RU 2018104283 A RU2018104283 A RU 2018104283A RU 2018104283 A RU2018104283 A RU 2018104283A RU 2018104283 A3 RU2018104283 A3 RU 2018104283A3
Authority
RU
Russia
Application number
RU2018104283A
Other languages
Russian (ru)
Other versions
RU2018104283A (en
RU2705540C2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018104283A3 publication Critical patent/RU2018104283A3/ru
Publication of RU2018104283A publication Critical patent/RU2018104283A/en
Application granted granted Critical
Publication of RU2705540C2 publication Critical patent/RU2705540C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2018104283A 2015-08-19 2016-08-10 Antibodies against tissue factor pathway inhibitor and use thereof RU2705540C2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562207229P 2015-08-19 2015-08-19
US62/207,229 2015-08-19
US201662360205P 2016-07-08 2016-07-08
US62/360,205 2016-07-08
PCT/IB2016/054814 WO2017029583A2 (en) 2015-08-19 2016-08-10 Tissue factor pathway inhibitor antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019125599A Division RU2815681C1 (en) 2015-08-19 2016-08-10 Antibodies against tissue factor pathway inhibitor and their use

Publications (3)

Publication Number Publication Date
RU2018104283A3 true RU2018104283A3 (en) 2019-09-19
RU2018104283A RU2018104283A (en) 2019-09-19
RU2705540C2 RU2705540C2 (en) 2019-11-07

Family

ID=56894019

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018104283A RU2705540C2 (en) 2015-08-19 2016-08-10 Antibodies against tissue factor pathway inhibitor and use thereof

Country Status (20)

Country Link
US (5) US10550200B2 (en)
EP (1) EP3337827A2 (en)
JP (4) JP6664467B2 (en)
KR (4) KR102536303B1 (en)
CN (2) CN114163531B (en)
AU (2) AU2016307967C9 (en)
CA (2) CA3174958C (en)
CO (1) CO2018001473A2 (en)
IL (3) IL302353A (en)
MX (2) MX391935B (en)
MY (1) MY195443A (en)
NZ (1) NZ739871A (en)
PE (2) PE20240142A1 (en)
PH (1) PH12018500211A1 (en)
RU (1) RU2705540C2 (en)
SA (1) SA518390944B1 (en)
SG (1) SG10201912817YA (en)
TW (1) TWI640538B (en)
WO (1) WO2017029583A2 (en)
ZA (1) ZA201800453B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072691A1 (en) † 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
CA2791685C (en) 2010-03-01 2019-07-23 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
KR102536303B1 (en) * 2015-08-19 2023-05-26 화이자 인코포레이티드 Tissue factor pathway inhibitor antibodies and uses thereof
KR102337683B1 (en) * 2018-09-21 2021-12-13 주식회사 녹십자 Highly efficient anti-TFPI antibody composition
CN113645995A (en) * 2018-10-11 2021-11-12 辉瑞公司 Dosage regimen of TFPI antagonists
CN112442127A (en) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 Monoclonal Antibody Against TFPI
AU2020348295A1 (en) 2019-09-16 2022-04-07 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof
MX2022005836A (en) * 2019-11-13 2022-06-09 Pfizer STABLE FORMULATION OF AQUEOUS ANTIBODIES.
KR102140653B1 (en) 2020-01-13 2020-08-03 이선재 Rice cake steamer
US20230340089A1 (en) * 2020-05-14 2023-10-26 City Of Hope Smc1a antibodies and uses thereof
EP4240765A2 (en) * 2020-11-06 2023-09-13 Novartis AG Antibody fc variants
CN113325185B (en) * 2021-07-09 2024-04-19 重庆鼎润医疗器械有限责任公司 Multi-level quality control product, preparation method thereof and application thereof in thromboelastography detection
EP4453012A1 (en) 2021-12-22 2024-10-30 Royal College of Surgeons in Ireland A conjugate for use in localising a molecule to the vascular endothelium
CN117285632A (en) * 2022-06-17 2023-12-26 安源医药科技（上海）有限公司 Monoclonal antibodies against TFPI and uses thereof
CN116903739B (en) * 2023-03-28 2023-12-15 中国人民解放军军事科学院军事医学研究院 An antibody against S100B protein and its application
WO2025124481A1 (en) * 2023-12-13 2025-06-19 苏州康宁杰瑞生物科技有限公司 Tfpi antibody used in the treatment of hemophilia

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
FI914427A0 (en) 1989-03-21 1991-09-20 Vical Inc EXPRESSION AV EXOGENA POLYNUCLEOTID- SEQUENTOR AND ETC RYGGRADSDJUR.
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (en) 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
JPH07507689A (en) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Specific tissue targeting methods and compositions
JPH09507741A (en) 1992-06-10 1997-08-12 アメリカ合衆国 Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
CA2145641C (en) 1992-12-03 2008-05-27 Richard J. Gregory Pseudo-adenovirus vectors
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
DE69434486T2 (en) 1993-06-24 2006-07-06 Advec Inc. ADENOVIRUS VECTORS FOR GENE THERAPY
EP0814154B1 (en) 1993-09-15 2009-07-29 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus vectors
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE437232T1 (en) 1993-10-25 2009-08-15 Canji Inc RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
NZ276305A (en) 1993-11-16 1997-10-24 Depotech Corp Controlled release vesicle compositions
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ES2297831T3 (en) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited RETROVIRIC VECTORS THAT PRESENT A REDUCED RECOMBINATION RATE.
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
EP0953052B1 (en) 1996-05-06 2009-03-04 Oxford BioMedica (UK) Limited Crossless retroviral vectors
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
JP4340339B2 (en) * 1998-07-31 2009-10-07 財団法人化学及血清療法研究所 Blood coagulation factor or blood coagulation control factor deficient model animal and method for producing the model animal
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
ATE553128T1 (en) 2002-12-24 2012-04-15 Rinat Neuroscience Corp ANTI-NGF ANTIBODIES AND METHOD OF USE THEREOF
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
AU2007358045A1 (en) * 2007-08-23 2009-02-26 Lfb Biotechnologies Anti-idiotypic antibodies which neutralise the inhibitory activity of an inhibitory antibody directed against the C1 domain of factor VIII
FR2933908B1 (en) 2008-07-16 2010-12-24 Renault Sas PROTECTIVE DEVICE FOR A MOTOR VEHICLE DOOR.
UA112050C2 (en) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI)
EP2379096B1 (en) * 2008-12-19 2019-10-30 Baxalta GmbH Tfpi inhibitors and methods of use
EP2379599B1 (en) 2008-12-22 2015-09-02 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
RS61082B1 (en) 2010-02-26 2020-12-31 Novo Nordisk As Stable antibody containing compositions
CA2791685C (en) 2010-03-01 2019-07-23 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
ES2621809T3 (en) * 2010-03-19 2017-07-05 Baxalta GmbH TFPI inhibitors and use procedures
RU2012153786A (en) 2010-05-28 2014-07-10 Ново Нордиск А/С STABLE MULTI-DOSE COMPOSITIONS CONTAINING ANTIBODY AND CONSERVANT
TW201212938A (en) * 2010-06-30 2012-04-01 Novo Nordisk As Antibodies that are capable of specifically binding tissue factor pathway inhibitor
KR20190079698A (en) * 2011-04-01 2019-07-05 바이엘 헬스케어 엘엘씨 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2013023251A1 (en) 2011-08-18 2013-02-21 Affinity Biosciences Pty Ltd Soluble polypeptides
JP6283017B2 (en) 2012-03-30 2018-02-21 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ Protease regulatory antibody
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014144577A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
WO2014144689A1 (en) 2013-03-15 2014-09-18 Bayer Healthcare Llc Pro-drug antibodies against tissue factor pathway inhibitor
WO2014140240A1 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
WO2015007880A1 (en) 2013-07-19 2015-01-22 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN107001437B (en) 2014-11-27 2021-10-29 公立大学法人横滨市立大学 Detection methods and drugs for ovarian clear cell adenocarcinoma
CN112225812B (en) 2015-02-25 2024-08-13 财团法人牧岩生命科学研究所 Novel antibodies that bind to TFPI and compositions comprising the same
KR102536303B1 (en) * 2015-08-19 2023-05-26 화이자 인코포레이티드 Tissue factor pathway inhibitor antibodies and uses thereof
CN113645995A (en) 2018-10-11 2021-11-12 辉瑞公司 Dosage regimen of TFPI antagonists

Also Published As

Publication number Publication date
KR102068915B1 (en) 2020-01-22
KR102536303B1 (en) 2023-05-26
IL256913B (en) 2022-02-01
US10550200B2 (en) 2020-02-04
US20210101998A1 (en) 2021-04-08
JP2018527922A (en) 2018-09-27
CN107922506A (en) 2018-04-17
CN114163531A (en) 2022-03-11
WO2017029583A3 (en) 2017-07-20
PE20240142A1 (en) 2024-02-01
MX2022004834A (en) 2022-05-16
KR20190097319A (en) 2019-08-20
TWI640538B (en) 2018-11-11
CN107922506B (en) 2021-11-09
PH12018500211A1 (en) 2018-08-13
CO2018001473A2 (en) 2018-05-10
KR102438650B1 (en) 2022-08-31
JP7303761B2 (en) 2023-07-05
IL289766B2 (en) 2023-10-01
NZ739871A (en) 2022-05-27
KR102068915B9 (en) 2023-10-12
MX2018002048A (en) 2018-04-13
SG10201912817YA (en) 2020-02-27
KR20180030936A (en) 2018-03-26
US12168698B2 (en) 2024-12-17
AU2016307967C1 (en) 2023-10-05
IL289766B1 (en) 2023-06-01
JP2024054266A (en) 2024-04-16
PE20180556A1 (en) 2018-04-02
IL302353A (en) 2023-06-01
AU2022201091B2 (en) 2025-03-20
CN114163531B (en) 2025-06-13
AU2016307967A1 (en) 2018-02-01
CA2939010A1 (en) 2017-02-19
US11634504B2 (en) 2023-04-25
JP6664467B2 (en) 2020-03-13
IL256913A (en) 2018-03-29
RU2018104283A (en) 2019-09-19
MX391935B (en) 2025-03-21
US10875929B2 (en) 2020-12-29
ZA201800453B (en) 2018-12-19
CA2939010C (en) 2025-09-16
KR20230074843A (en) 2023-05-31
JP2022084623A (en) 2022-06-07
CA3174958C (en) 2025-05-27
RU2705540C2 (en) 2019-11-07
AU2022201091A1 (en) 2022-03-10
US20230416405A1 (en) 2023-12-28
US20200190214A1 (en) 2020-06-18
BR112018001478A2 (en) 2018-09-18
MY195443A (en) 2023-01-21
SA518390944B1 (en) 2022-02-08
US20170073428A1 (en) 2017-03-16
KR20220136381A (en) 2022-10-07
NZ756365A (en) 2025-02-28
AU2016307967C9 (en) 2025-02-20
EP3337827A2 (en) 2018-06-27
TW201718659A (en) 2017-06-01
JP2020096627A (en) 2020-06-25
IL289766A (en) 2022-03-01
AU2016307967B2 (en) 2022-02-17
US20250145732A1 (en) 2025-05-08
CA3174958A1 (en) 2017-02-19
WO2017029583A2 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
BR112018002665A2 (en)
RU2018104283A3 (en)
BR112018004058A2 (en)
BR112017026493A2 (en)
BR112018004511A2 (en)
BR0009373B1 (en)
BR0009761B1 (en)
CN303068057S (en)
CN303066876S (en)
CN303065240S (en)
CN303069271S (en)
CN303070074S (en)
CN303070995S (en)
CN303074392S (en)
BR0317692B1 (en)
BR0312418B1 (en)
BR0206505B1 (en)
BR0203273B1 (en)
BR0008719B1 (en)
BR0009942B1 (en)
BR0008789B1 (en)
BR0009757B1 (en)
BR0009717B1 (en)
BR0009649B1 (en)
BR0001810B1 (en)